Cybin Announces CDN$20 Million Bought Deal Offering

Lobe Sciences Announces Management Changes and New Director

Numinus Announces Grant of Stock Options

EGF Theramed Raises $352,502 in First Tranche of Private Placement

Awakn Life Sciences Appoints CRO to Conduct Phase II Study of MDMA as a Treatment for Alcohol Use Disorder

Optimi Health Corp. Receives Health Canada Psychedelic Research Exemption and Files Preliminary Prospectus for Initial Public Offering of Units

Core One Labs Completes Sale of Non-Core Assets

Psyched Wellness Completes Initial Data Review to Determine Clinical Path for Muscimol

NeonMind Appoints Dr. Frank Russo to Lead Development of Music-Based Program for Psilocybin Clinical Trials

Tryp Therapeutics Strengthens Board of Directors with Appointment of Gregory M. McKee

Revive Therapeutics Announces Research Collaboration with North Carolina State University for Natural Biosynthesis Enzymatic Platform To Develop Psilocybin

MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience

Mindset Pharma Invited to Present at Upcoming Canaccord Genuity Mental Health Conference

Entheon Biomedical Corp. Announces Acquisition of HaluGen Life Sciences Inc.

New Wave Holdings subsidiary, Way of Will Inc. is pleased to announce its launch of high-quality mushroom products for Q1 2021

Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units